In a move underscoring Pfizer’s commitment to advancing its hematology portfolio, Erinn Hoag Goldman has been promoted to Senior Director, US Medical Affairs, Hematology.
Erinn Hoag Goldman’s journey at Pfizer has been marked by progressive leadership roles over nearly 7 years, culminating in her recent appointment. Her tenure at Pfizer began with a focus on multiple myeloma, where she made significant strides as Medical Director and then as Global Medical Director, Multiple Myeloma, before stepping into her latest position.
Goldman’s extensive background in medical affairs and strategic medical communication, developed over more than 7 years at ArticulateScience, a member of Nucleus Global, has equipped her with a unique blend of skills and insights. As Vice President, Managing Director there, she led a sizable team and provided strategic oversight on global accounts, focusing on medical education, communication, and publication planning for pharmaceutical and biotech clients.
Her career is distinguished not only by her leadership positions but also by her deep involvement in strategic oversight of scientific staff and initiatives, particularly in oncology, hematology, and infectious disease. This experience will undoubtedly serve her well as she embarks on her new role at Pfizer, where the focus is on delivering groundbreaking therapies in hematology.
As Senior Director, Goldman is poised to drive forward Pfizer’s hematology initiatives, leveraging her extensive experience to foster innovation, enhance patient care, and lead the company’s efforts in supporting organizations that champion the development of new treatments for blood disorders. Her leadership is expected to have a substantial impact on Pfizer’s ongoing success and its contributions to the medical field.
